OrthoPediatrics Corp. is a global medical device company headquartered in Warsaw, Indiana, specializing in pediatric orthopedic care. The company designs, develops, and markets anatomically appropriate implants, instruments, and specialized braces tailored to the needs of pediatric surgeons, orthotists, and their patients. Its offerings include trauma and deformity correction devices, scoliosis treatment systems, sports medicine products, and clinical services aimed at improving the lives of children with orthopedic conditions.
- Trauma and Deformity - Provides implants and instruments for correcting pediatric trauma and deformities, including systems like PediLoc®, Cannulated Screws, and the Fassier-Duval Telescopic Intramedullary System®.
- Scoliosis - Offers innovative solutions for scoliosis treatment, including minimally invasive systems like RESPONSETM Spine and BandLoc™.
- Sports Medicine/Other - Delivers products for pediatric sports medicine and other orthopedic needs, such as ACL Reconstruction Systems and specialized bracing options.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
David R. Bailey ExecutiveBoard | President and Chief Executive Officer | David R. Bailey has served as the President and Chief Executive Officer at KIDS since June 1, 2021. He joined the company in 2007 and was appointed as a board member on November 3, 2021. | View Report → | |
Fred L. Hite ExecutiveBoard | Chief Financial Officer | Fred L. Hite has served as CFO of OrthoPediatrics Corp. since February 2015 and concurrently as COO since June 2020. He has also been a Director since August 2015 and previously served as CFO and Investor Relations Officer at Symmetry Medical Inc. from 2004 to 2014. | ||
Daniel J. Gerritzen Executive | Executive Vice President (Legal), General Counsel, and Secretary | Daniel J. Gerritzen has served as General Counsel since 2009, Secretary since 2013, and became Executive Vice President in 2022 at KIDS, demonstrating his extensive legal and executive leadership. Previously, he was a partner and continues to serve as Of Counsel at Dentons Bingham Greenebaum LLP. | ||
Gregory A. Odle Executive | President of Scoliosis | Gregory A. Odle is the President of Scoliosis at OrthoPediatrics Corp since 2022. He previously served as Executive Vice President from 2011 to 2022 and was a Board of Directors member from 2007 to 2013. | ||
Joseph W. Hauser Executive | President of Trauma, Deformity, and OPSB | Joseph W. Hauser is the President of Trauma, Deformity, and OPSB at OrthoPediatrics since 2024. Previously, he served as President of Trauma and Deformity Correction from 2022 to 2024 and as Senior Vice President from 2021 to 2022. | ||
Bryan W. Hughes Board | director | Managing Director and Group Head of Medical Technology Investment Banking at P&M Corporate Finance, LLC | Bryan W. Hughes has served as a director at OrthoPediatrics Corp (KIDS) since 2012. He is also the Managing Director and Group Head of Medical Technology Investment Banking at P&M Corporate Finance, LLC since 2008. | |
David R. Pelizzon Board | Director | President of Squadron Capital LLC; Director at Alphatec Holdings, Inc. | David R. Pelizzon has served as Director at KIDS since 2011, playing a key role in the company’s board governance. He also brings extensive leadership experience from his roles as President of Squadron Capital LLC since 2008 and Director at Alphatec Holdings, Inc. since June 2020. | |
Mark C. Throdahl Board | Chairman of the Board | Chairman of OrthoPediatrics Corp. since 2024 , previously served as CEO from January 2011 to June 2021. | ||
Terry D. Schlotterback Board | Lead Independent Director | Chairman of the Board, Nextremity Products Inc. ; Board Member, OrthoLazer Inc. ; Advisor for Ignite Orthopedics Inc. | Terry D. Schlotterback has been a director at KIDS since 2009, currently serving as Lead Independent Director since June 2021 and previously as Chairman of the Board from September 2013 to June 2021. |
- Given the international revenue growth was only 5% in Q4 2024 due to deliberate shipment holds in South America to manage receivables affected by currency fluctuations, how do you plan to mitigate these currency risks and stimulate international growth moving forward?
- With gross profit margin decreasing to 68% in Q4 2024 from 71% in the prior year due to reclassification of certain expenses into cost of goods sold, what specific actions are you taking to improve gross margins, and is there potential for upside as you scale manufacturing and launch new products?
- Considering the $3.7 million restructuring charge associated with closing your Israel office and consolidating ApiFix production into the U.S., what impact will this have on your supply chain and production timelines, and are there risks related to this consolidation?
- You mentioned reducing set deployments to $15 million in 2025 compared to previous years; is there a risk that this lower level of investment might constrain growth in your Trauma and Deformity business in the future, potentially necessitating a larger deployment in subsequent years?
- With products like DF2 experiencing demand that exceeds expectations and current manufacturing capacity, how are you addressing supply constraints and what steps are you taking to scale manufacturing to meet both domestic and international demand without compromising quality?
Research analysts who have asked questions during ORTHOPEDIATRICS earnings calls.
Matthew O'Brien
Piper Sandler & Co.
4 questions for KIDS
Ryan Zimmerman
BTIG
3 questions for KIDS
Frederick Wise
Stifel
2 questions for KIDS
Joseph Conway
Needham & Company, LLC
2 questions for KIDS
Mike Matson
Needham & Company, LLC
2 questions for KIDS
Ben Haynor
Lake Street Capital Markets
1 question for KIDS
Benjamin Haynor
Lake Street Capital Markets
1 question for KIDS
Richard Newitter
Truist Securities
1 question for KIDS
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
The company operates in the competitive orthopedic industry, which is subject to rapid technological changes and influenced by new product introductions. It is noted as a competitor in all three product categories, and the company's ability to compete depends on developing proprietary products that are cost-effective, safe, and effective, while also maintaining a dedicated selling organization viewed as a consultative resource by pediatric orthopedic surgeons. | |
The company is identified as a competitor in the orthopedic industry, which is characterized by intense competition and rapid changes. Competitors may develop new devices or treatment alternatives that could render the company's products obsolete or uncompetitive. Many competitors have substantially greater sales and financial resources, entrenched relationships with orthopedic surgeons, and more experience in launching and marketing products. | |
The company faces competition from this entity in the orthopedic industry, which is highly sensitive to the introduction of new products. Competitors may gain market advantages by developing and patenting competitive products earlier or obtaining regulatory clearances more rapidly. The frequent introduction of competing products may create market confusion, making it difficult to differentiate the benefits of the company's products. | |
This competitor is mentioned as operating in the orthopedic industry, which is intensely competitive and subject to rapid changes. The company notes that competitors may specialize in specific products or focus on particular market sectors, making it challenging to increase its overall market position. | |
Hanger clinics | The company identifies this entity as a competitor in the orthopedic industry, emphasizing the need to develop proprietary products that are cost-effective, safe, and effective to compete successfully. Competitors may employ pricing strategies that could adversely affect the pricing of the company's products. |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Orthotic and Prosthetic Device Clinics in Virginia and Maryland | 2024 | Boston Orthotics & Prosthetics acquired these clinics on July 1, 2024 for a total consideration of $950,000—split evenly between a cash payment of $475,000 and a promissory note payable in six quarterly installments at 5.0% per annum—acquiring associated clinic inventory. |
Boston Orthotics & Prosthetics | 2024 | OrthoPediatrics Corp. completed its acquisition of Boston O&P on January 5, 2024 for $22 million in cash, with additional restricted stock awards totaling approximately 83,000 shares (valued at $2.5 million), thereby expanding its specialty bracing division and product portfolio and resulting in recognized goodwill and intangible assets, supported by an $80 million debt financing agreement. |
Medtech Concepts LLC | 2023 | OrthoPediatrics Corp. acquired Medtech Concepts LLC on May 1, 2023 for about $15.274 million, structured with an upfront cash payment, issuance of unregistered shares, and future annual payments; the acquisition provided an early-stage enabling technology platform that combines hardware, software, and data analytics aimed at enhancing perioperative efficiency. |
Rhino Pediatric Orthopedic Designs, Inc. | 2023 | Completed on July 1, 2023, the acquisition of Rhino Pediatric Orthopedic Designs, Inc. for $1,024,000 (comprising $546,000 in cash and a stock issuance of 11,133 shares) secured key assets including pediatric orthopedic products such as the Cruiser™, Kicker™, and Rhino Stomper™. |
MD Orthopaedics, Inc. | 2022 | OrthoPediatrics Corp. acquired MD Orthopaedics, Inc. on April 1, 2022 for approximately $18.5 million—through a mix of cash, unregistered stock (173,241 shares), and $2.5 million in restricted stock awards—to expand into non-operative pediatric treatments with its patented clubfoot products and boost a total addressable market by an estimated $600 million. |
Pega Medical Inc. | 2022 | On July 1, 2022, Pega Medical Inc. was acquired for a purchase price of about $32.045 million, primarily in cash (with approximately $1.052 million held in escrow) along with additional stock issuance and restricted stock units; the deal, supported by an increased revolving credit facility, enhanced OrthoPediatrics’ portfolio with trauma and deformity correction devices and widened its global market reach. |
Recent press releases and 8-K filings for KIDS.
- OrthoPediatrics Corp. reported total revenue of $61.2 million for the three months ended September 30, 2025, marking a 12% increase compared to Q3 2024.
- For Q3 2025, the company recorded a net loss of ($11.8 million) and a diluted EPS of ($0.50), while Adjusted EBITDA was $6.2 million.
- The company provided full-year 2025 guidance, projecting revenue between $233.5 to $234.5 million, representing a 14% to 15% total revenue growth, and Adjusted EBITDA of $15.0 to $17.0 million.
- Strategic expansion includes the acquisition of Boston Orthotics & Prosthetics for $22 million cash in January 2024, establishing the OrthoPediatrics Specialty Bracing (OPSB) division, which plans to launch 4 products in 2024 and 5 in 2025 and expand into 4 new markets in 2025.
- OrthoPediatrics Corp. reported Q3 2025 worldwide revenue of $61.2 million, an increase of 12% compared to the prior year period, driven by strong performance in Trauma and Deformity, Scoliosis, and OPSB, but offset by a decline in 7D unit sales and LATSAM stocking.
- The company's gross profit margin improved to 74% in Q3 2025, up from 73% in Q3 2024, primarily due to a favorable product sales mix. Adjusted EBITDA for Q3 2025 was $6.2 million, a 56% improvement over Q3 2024.
- OrthoPediatrics adjusted its full-year 2025 revenue guidance to $233.5 million-$234.5 million, representing 14%-15% year-over-year growth, while reiterating full-year adjusted EBITDA guidance of $15 million-$17 million.
- The company anticipates achieving its first quarter of free cash flow positivity in Q4 2025 and significantly improved free cash flow usage to $3.4 million in Q3 2025 compared to $11.7 million in Q3 2024.
- Key product developments include the FDA approval of the 3P Small and Mini system, with first cases expected early next year, and continued expansion of OPSB clinics from 26 to over 40 since January 2024.
- OrthoPediatrics Corp. reported Q3 2025 worldwide revenue of $61.2 million, a 12% increase compared to the prior year, driven by strong performance in Trauma and Deformity, Scoliosis, and OrthoPediatrics Specialty Bracing (OPSB).
- Revenue growth was below expectations due to zero 7D capital sales in the quarter and continued headwinds from stocking and set sales in Latin and South America (LATSAM).
- Despite the revenue shortfall, the company achieved a 56% improvement in Adjusted EBITDA to $6.2 million and significantly reduced free cash flow usage to $3.4 million.
- For the full year 2025, OrthoPediatrics adjusted its revenue outlook to a range of $233.5 million to $234.5 million but reiterated its Adjusted EBITDA guidance of $15 million to $17 million.
- The company expects to achieve positive free cash flow in Q4 2025 and breakeven free cash flow in 2026.
- OrthoPediatrics Corp. reported Q3 2025 worldwide revenue of $61.2 million, an increase of 12% compared to the prior year, driven by strong performance in Trauma and Deformity, Scoliosis, and OrthoPediatrics Specialty Bracing (OPSB).
- Adjusted EBITDA for Q3 2025 significantly improved by 56% to $6.2 million, and free cash flow usage decreased by $8.2 million.
- Revenue fell short of expectations due to 7D capital sales not closing and continued headwinds from LATSAM international stocking and set sales.
- The company reaffirmed its full-year 2025 Adjusted EBITDA outlook of $15 million to $17 million and expects full-year revenue to range from $233.5 million to $234.5 million.
- Management is confident in generating positive free cash flow in Q4 and achieving breakeven free cash flow in 2026, focusing on profitable revenue and improved cash flow.
- OrthoPediatrics (KIDS) is exclusively focused on pediatric orthopedics, serving 100% of top children's hospitals in the U.S. with a broad product portfolio and addressing a total global addressable market of $6.2 billion.
- The company has demonstrated consistent year-over-year revenue growth, with a 24% CAGR since IPO (excluding COVID-impacted 2020). It reported $204.7 million in revenue for FY2024 and provided FY2025 revenue guidance of $233.5 million to $234.5 million.
- Strategic initiatives include aggressive investment in R&D with new product launches such as VerteGlide (launched August 2025) and ELLITM (FDA submission expected by early 2026), and M&A activities including the $22 million cash acquisition of Boston Orthotics & Prosthetics in January 2024.
- For Q3 2025, OrthoPediatrics reported revenue of $61.2 million and Adjusted EBITDA of $6.2 million.
- OrthoPediatrics reported preliminary third-quarter 2025 revenue of $61.2 million, which fell short of expectations due to delayed 7D capital sales and continued growth headwinds in Latin and South America (LatAm).
- The company decreased its full-year 2025 revenue guidance to a range of $233.5 million to $234.5 million, down from the previous range of $237 million to $242 million, representing year-over-year growth of 14% to 15%.
- The long-term outlook for annual revenue growth has been adjusted to 12% or greater for the next several years, reflecting the uncertainty and timing of 7D capital sales and LatAm business.
- Despite the revenue adjustments, OrthoPediatrics reiterated its full-year 2025 gross margin guidance of 72% to 73% and adjusted EBITDA guidance of $15 million to $17 million.
- The company remains committed to achieving positive free cash flow in 2025 and reaching free cash flow breakeven by 2026, with improvements expected from working capital utilization.
- OrthoPediatrics reported preliminary unaudited third quarter 2025 net revenue of approximately $61.2 million, representing 12% growth compared to the third quarter of 2024.
- The company has revised its full-year 2025 revenue guidance to a range of $233.5 million to $234.5 million, a decrease from the previous guidance of $237.0 million to $242.0 million.
- This revision is primarily due to delayed 7D capital sales and headwinds within the Latin and South America segment of the business.
- OrthoPediatrics reiterated its adjusted EBITDA guidance of $15.0 million to $17.0 million for the full year 2025.
- OrthoPediatrics Corp. is the only company focused exclusively on pediatric orthopedics, having helped over 1,200,000 children with its devices. The global market is estimated at $6.2 billion, with a U.S. addressable market of $2.6 billion.
- The company has achieved nearly 20% year-over-year growth for almost two decades. For 2025, OrthoPediatrics projects revenue between $237 million and $242 million and adjusted EBITDA between $15 million and $17 million.
- OrthoPediatrics anticipates achieving free cash flow breakeven in Q4 2025 and for the full year 2026.
- Key growth catalysts include the upcoming launch of the Vertiglyde system and the development of ELE, an electromechanical growing technology with breakthrough device designation, aiming for FDA approval and first surgeries next year.
- The company is also expanding its specialty bracing business (OPSB), having grown from 26 to over 40 clinics since the acquisition of Boston OMP, with plans to expand into 26 of 80 territories within the next three years.
- OrthoPediatrics Corp reported Q2 2025 revenue of $61.1 million, a 16% growth year-over-year, alongside a net loss of ($7.1 million) and diluted EPS of ($0.30). The company's Adjusted EBITDA for the quarter was $4.1 million.
- The company provided full-year 2025 revenue guidance of $237.0 million to $242.0 million, representing 16% to 18% growth, and Adjusted EBITDA guidance of $15.0 million to $17.0 million.
- Key strategic developments include the FDA approval of VerteGlide™ in April 2025 and the acquisition of Boston Orthotics & Prosthetics on January 5, 2024, for $22 million cash, expanding its specialty bracing division.
- OrthoPediatrics Corp. achieved record high total revenue of $61.1 million for the second quarter of 2025, an increase of 16% compared to the second quarter of 2024.
- Adjusted EBITDA for Q2 2025 increased by 58% to $4.1 million.
- The company reported a GAAP diluted loss per share of ($0.30) and an improved non-GAAP diluted loss per share of ($0.11) for the second quarter of 2025.
- OrthoPediatrics increased its full-year 2025 revenue guidance to a range of $237.0 million to $242.0 million, representing 16% to 18% growth over 2024 revenue.